Introduction
Lamotrigine (LTG) is widely used for the treatment of epilepsies with simple-and complex-partial as well as generalized seizures. 1 Many pharmacokinetic effects of other anticonvulsive drugs or other agents (e.g. hormones) on serum levels of LTG have been described. [2] [3] [4] As influences of smoking on drugs metabolized by glucuronidation such as lorazepam and oxazepam have been reported and LTG is also substrate for glucuronidation, 5 an effect on LTG appears to be possible. Furthermore, nicotine is known to decrease the anticonvulsive effect of LTG in a mice model. 6 Methods LTG serum levels of 44 Caucasian patients with epilepsy treated with LTG in monotherapy were retrospectively examined. Except a possible intake of oral contraceptive pills in female patients, no other medication that could influence LTG serum Seizure (2008) Summary The influence of smoking on lamotrigine (LTG) serum levels in 44 patients with epilepsy treated with LTG in monotherapy was examined. Fifteen patients were smokers (range: three cigarettes per month -three packages per day) and 29 were non-smokers. Analyzing 204 samples, smokers had a significantly lower serum levelto-dose ratio than non-smokers (0.0657 mmol mg/l (smokers) vs. 0.0785 mmol mg/l (non-smokers)) ( p = 0.0014). Analyzing only male patients, the same relationship with an almost equally high level of significance could be demonstrated ( p = 0.008). Our data indicate that the demonstrated effect of smoking on LTG metabolism is likely to be mediated via UDPGT2B7, as LTG is not a substrate of cytochrome P450 isoenzymes and UDPGT1A4 activity may not be affected by nicotine, but the exact mechanism underlying the demonstrated effect remains uncertain. These findings are likely to be independent from hormonal changes, as they could also be reproduced in the group of male patients. Therefore, the effect of smoking on blood levels of LTG has to be taken into account in the evaluation of treatment with this drug. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. levels were taken. Fifteen of the patients (10 females and five males) were smokers (three cigarettes/month -three packages/day, five patients smoked less than 10 cigarettes/day) and 29 (15 females, 14 males) non-smokers. Allowing repeated measurements in single patients, 204 samples were collected on various daytimes and analyzed. Blood samples were taken with sufficient time to the last alteration in the dose of LTG, to assume a steady state. All patients were recruited as in-or outpatients in our epilepsy center. LTG serum levels were determined using reverse phase high performance liquid chromatography (HPLC) utilizing acetonnitrile-phosphate buffer. The statistical comparison between LTG serum levels was performed by SPSS 14.0 Software using K&S-Test, correlation by Pearson and one-factor ANOVA.
Results
Characteristics of the study population are given in Table 1 .
All data showed normal distribution in the K&S-Test. The comparison between LTG serum levels revealed a highly significant ( p = 0.00138, Fig. 1 ) difference of the quotient of LTG serum level and dosage between smokers and non-smokers. Analyzing only male patients, the same relationship with an almost equally high level of significance could be demonstrated ( p = 0.008).
Although there was no statistically significant correlation between the number of cigarettes per day and LTG serum level-to-dose ratio, there was a trend pointing to a dose effect of smoking on LTG serum levels in the Pearson correlation (r = À0.127 mmol/l mg, p = 0.069).
Discussion
Our data indicates significant effects of smoking on serum levels of LTG. Smokers showed a significantly lower LTG serum level-to-dose ratio than non-smokers (approximately 16%). Because our patients were examined on various occasions and daytimes and because a strict compliance, especially in the outpatients of our sample, cannot be generally assumed, this effect may even be underestimated. Differences of multiple measurements of LTG serum level of one patient did never exceed ranges explained by pharmacokinetics due to various time of LTG intake prior to the blood sampling. The inclusion of patients with a very mild consumption 652 C. Reinsberger et al. of cigarettes (three per month) into the group of smokers may also contribute to an underestimation of this effect. Because the numbers in the examined population would have been too small for statistical analysis, it was not possible to consider only heavy smokers in the smoker group. In addition, due to the relatively low number of smokers, possible dose effects of smoking could not have been detected with statistical significance. Since the majority of smokers were female, whereas the majority of non-smokers were male a possible effect of intake of oral contraceptive pills and possible early pregnancies which were not assessed in our study could explain the observed difference of LTG serum level to dose ratio between the two groups. However, the demonstration of the same results only considering male patients points to the relevance and validity of the overall results.
Tobacco smoke and nicotine, respectively, induce cytochrome P450 (CYP)1A1, CYP1A2, CYP 2A1/2A2, CYP 2B1/2B2 and CYP 2E1 as well as glucuronidation, 7 but these effects could only be demonstrated in 1A9 and 2B7 subtypes of uridine diphosphate glucuronyltransferases (UDPGT) with lorazepam, oxazepam, propanolol and acetaminophen (paracetamol) as substrates so far. However, LTG is metabolized by glucuronidation via UDPGT1A4, 5, 8 or UDPGT2B7. 8 Therefore, our data indicate that the demonstrated effect of smoking on LTG metabolism is likely to be mediated via UDPGT2B7, as LTG is not a substrate of cytochrome P450 isoenzymes 9 and UDPGT1A4 activity may not be affected by nicotine, but the exact mechanism underlying the demonstrated effect remains uncertain.
Although doubts about the usefulness of LTG serum levels in the clinical management of patients taking LTG remain, 10 LTG serum levels are often utilized to monitor compliance and assess tolerability and efficacy. 11 As smoking is still a widely spread habit in the population smoking habits should be included in the history of patients taking LTG and considered in the interpretation of LTG serum levels.
Thus, our preliminary data demonstrating smoking to cause a significant decrease of the LTG serum level-to-dose ratio has to be confirmed by further prospective studies with a higher number of patients, with a more detailed assessment of smoking habits and hormonal issues in women.
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